12:00 AM
 | 
May 15, 2006
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 5/12 cls
Acorda (ACOR) Cowen Phil Nadeau New Market outperform -4% $4.88
Rodman Elemer Piros New Market outperform
Nadeau is "cautiously optimistic" about an ongoing Phase III trial of ACOR's Fampridine-SR for walking disability associated with multiple sclerosis (MS). He said the indication is an unmet need and occurs in 60-70% of MS patients.
Piros set a $14 target. He estimates Fampridine-SR could have peak sales of more than $400M by 2017, following an expected launch in 2009.
Alnylam (ALNY) Needham Mark Monane Price target...

Read the full 616 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >